Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine
about
Monitoring of the Immune Dysfunction in Cancer PatientsModification of the tumor microenvironment as a novel target of renal cell carcinoma therapeuticsJAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.Tumor antigen cross-presentation and the dendritic cell: where it all begins?TGFβ in T cell biology and tumor immunity: Angel or devil?Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches.Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.Nephrectomy is necessary in the treatment of metastatic renal cell carcinoma.The current status of immunobased therapies for metastatic renal-cell carcinoma.
P2860
Q28072712-E519D088-245B-4B51-8655-10C505646BABQ28393614-6EA4148A-1CF1-4A61-9B6E-D6B2F47C3E9AQ33747097-4B8E0279-91FC-48FE-9833-3A3FF53B0932Q34210664-4D15A939-7095-44FC-AC5E-99634DC4B0D2Q34276027-1752F4D1-5022-4EED-B749-B449F7062B40Q35057739-C98395E5-B109-4DF6-AC73-2E5F5D401349Q35070193-7D736399-2515-4AC8-B042-24C244EC323FQ35669197-00172F2E-913D-48EE-8EC1-0F8F43895A21Q36785683-2EB0BAA0-663A-4B34-844F-6B0175AE2049Q38099023-9E8CE0AF-FE6B-406C-AF5D-3D0344B35B00Q38810926-E4D61CC0-EFCF-4E28-90BB-FA9BD4A69ACEQ38902037-6232BA1C-4A7F-4AA7-8505-563909503D50Q40348649-C2DCD34F-A3FC-4444-98EA-AD03E6F29BB9Q42929933-DD527B50-B4CC-4988-894F-8092A6CAEE9CQ47097756-169FEA6B-6DDE-4C33-A663-00F558362BB8
P2860
Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Dysfunctional DC subsets in RC ...... effective anti-cancer vaccine
@ast
Dysfunctional DC subsets in RC ...... effective anti-cancer vaccine
@en
type
label
Dysfunctional DC subsets in RC ...... effective anti-cancer vaccine
@ast
Dysfunctional DC subsets in RC ...... effective anti-cancer vaccine
@en
prefLabel
Dysfunctional DC subsets in RC ...... effective anti-cancer vaccine
@ast
Dysfunctional DC subsets in RC ...... effective anti-cancer vaccine
@en
P2093
P2860
P50
P1433
P1476
Dysfunctional DC subsets in RC ...... effective anti-cancer vaccine
@en
P2093
F P Selvaggi
G Castellano
L Gesualdo
M Battaglia
P2860
P304
P356
10.1016/J.MOLIMM.2008.09.015
P577
2008-11-28T00:00:00Z